This may result in reduced functionality and affect the graphical presentation of this site.However, all content will still be available.
This product has been shown effective for the vaccination of healthy horses 6 months of age or older against Eastern and Western encephalomyelitis (EEE and WEE) viruses, equine influenza virus (EIV), equine herpesvirus type 1 (EHV-1), equine herpesvirus type 4 (EHV-4), tetanus and West Nile Virus. Duration of immunity has been shown at 6 months for EIV. Duration of immunity for Eastern and Western encephalomyelitis viruses, EHV-1, EHV-4, tetanus and West Nile Virus has not been established. For more information regarding safety and efficacy data, go to productdata.aphis.usda.gov. This product has been shown to be effective against virus shedding of EIV, EHV-1 and EHV-4, and encephalitis and viremia caused by West Nile Virus.
In the immunogenicity intrathecal challenge study, the West Nile virus fraction of the Prestige 5 + WNV, Prestige 3 + WNV and Prestige WNV vaccines demonstrated a statistically significant reduction for the following parameters in vaccinates as compared to controls1:
1. Data on file, Merck Animal Health.
For primary vaccination aseptically administer 1 mL intramuscularly, repeat with a single dose in 3 - 4 weeks. Historically, annual revaccination with this product has been recommended. The need for this booster has not been established. The presence of maternal antibody is known to interfere with the development of active immunity in foals and additional boosters will be required in most young animals. For more information on revaccination frequency, consult your veterinarian.
Copyright © 2019 Intervet Inc., a subsidiary of Merck & Co., All Rights Reserved. Intervet Inc. d/b/a Merck Animal Health, Madison, NJ 07901